Zhaoxing Wu
Hangzhou, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications
DHCR7 drives AML development through the IL6/JAK2/STAT3 signalling pathway.
Journal: British journal of haematology
Published: August 01, 2025
Targeting CaMKIIδ overcomes therapy resistance in acute myeloid leukemia by suppressing the STAT3/CDK6/BCL-2 survival axis.
Journal: Journal of leukocyte biology
Published: May 15, 2025
DHCR7 as a Prognostic and Immunological Biomarker in Human Pan-Cancer: A Comprehensive Evaluation.
Journal: Cancer reports (Hoboken, N.J.)
Published: March 09, 2025
HERV-K TM Subunit Elicits CD8+ T Cell Anergy and Tumor Immune Evasion via Targeting CD3 Coreceptor ε in AML and PDAC.
Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: December 23, 2024
An oral triple pill-based cocktail effectively controls acute myeloid leukemia with high translation.
Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: July 06, 2023
A Selective Small-Molecule c-Myc Degrader Potently Regresses Lethal c-Myc Overexpressing Tumors.
Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: September 29, 2021
Natural small molecule triptonide inhibits lethal acute myeloid leukemia with FLT3-ITD mutation by targeting Hedgehog/FLT3 signaling.
Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: August 10, 2020
CAMKIIγ is a targetable driver of multiple myeloma through CaMKIIγ/ Stat3 axis.
Journal: Aging
Published: February 25, 2020
Aberrant activation of RPB1 is critical for cell overgrowth in acute myeloid leukemia.
Journal: Experimental cell research
Published: July 30, 2019
Last Updated: 09/26/2026